Filtered By:
Condition: Thrombosis
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 1175 results found since Jan 2013.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
Abstract: Background: Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done mostly in Western countries. It remains to be seen whether dabigatran will be cost effective in a practice environment where warfarin is significantly underused and the costs of both warfarin and international normalized ration INR monitoring are cheap.Methods: We performed a cost-effectiveness analysis with a Markov model to evaluate the value of dabigatran to prevent stroke and systemic embolism in patients with atrial fibrillation (AF) in Taiwan. Dabigatran was given through sequential dosing, where patients
Source: Thrombosis Research - March 17, 2014 Category: Hematology Authors: Chia-Hsien Chang, Yea-Huei Kao Yang, Jyh-Hong Chen, Li-Jen Lin Tags: Clinical Studies Source Type: research

Novel anticoagulants in patients with mechanical heart valves
Commentary on: Eikelboom JW, Connolly SJ, Brueckmann M, et al.. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206. Context Novel anticoagulants (including the direct thrombin inhibitor dabigatran etixilate) and oral factor Xa inhibitors have similar or superior efficacy and safety to warfarin for reducing thromboembolic stroke in patients with atrial fibrillation, and for prevention of deep venous thrombosis. Eikelboom and colleagues set out to examine whether these novel anticoagulants could be used as an alternative to warfarin in patients with mechanical heart valves. Method...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Stewart, R. A. H. Tags: Drugs: cardiovascular system, Stroke, Venous thromboembolism Therapeutics Source Type: research

Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants.
CONCLUSIONS: Little is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable. PMID: 24821640 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - March 1, 2014 Category: Neurology Authors: Stöllberger C, Finsterer J Tags: Neurol Neurochir Pol Source Type: research

Pulmonary Arteriovenous Malformation as a Cause of Embolic Stroke: Case Report and Review of the Literature
We describe an 82-year-old woman without history of respiratory or neurological diseases, who presented at our observation unit with acute onset of cerebral ischemia. Clinical, laboratory and radiological findings diagnosed a PAVM. Key Messages: Usually, endovascular procedures based on embolization or, alternatively, surgery represent the recommended treatment. However, both hormonal therapy and thrombolytic therapy can be used. In our patient, treatment with warfarin induced a remission of symptoms. This strategy should be tested in larger studies.Intervent Neurol 2014;3:27-30
Source: Interventional Neurology - November 10, 2014 Category: Neurology Source Type: research

Embolic Stroke during Apixaban Therapy for Left Atrial Appendage Thrombus
Left atrial appendage (LAA) thrombus is associated with atrial fibrillation (AF) and is a powerful predictor of cardiogenic thromboembolism. Warfarin is an established anticoagulant therapy for patients with LAA thrombus to prevent thromboembolic complications. Apixaban is superior to warfarin in the prevention of thromboembolic complications in patients with AF, and there are case reports showing apixaban-associated resolution of LAA thrombus; however, the efficacy and safety of apixaban for the treatment of LAA thrombus remains unproven.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2015 Category: Neurology Authors: Masaki Ohyagi, Kazuha Nakamura, Mutsufusa Watanabe, Hiroto Fujigasaki Tags: Case Report Source Type: research

Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
ConclusionsWe report the largest series of cerebral vein thrombosis patients treated with dabigatran. Clinical outcome was excellent in most patients and not different from other studies. Dabigatran could possibly be considered an alternative to warfarin; nevertheless, further prospective assessment with randomized controlled studies is warranted.
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Marcelo D. Mendonça, Raquel Barbosa, Vera Cruz‐e‐Silva, Sofia Calado, Miguel Viana‐Baptista Tags: Research Source Type: research

Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery
The benefit of early anticoagulation for stroke prophylaxis in atrial fibrillation after coronary artery bypass graft (CABG) surgery is uncertain. We therefore studied what proportion of ischemic strokes in patients with atrial fibrillation early after CABG surgery were potentially preventable by anticoagulation with warfarin.
Source: Thrombosis Research - February 24, 2015 Category: Hematology Authors: S. Schulman, I. Cybulsky, J. Delaney Tags: Regular Article Source Type: research

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)
ConclusionsIn this Phase II study in patients with NVAF, a lower bleeding rate was observed in the 120 mg daily darexaban group compared with warfarin with a reduction in plasma D‐dimer as marker for hemostasis. Further investigation of the optimal dose of darexaban for the prevention of stroke in patients with NVAF would need to be considered.
Source: Journal of Thrombosis and Haemostasis - July 15, 2015 Category: Hematology Authors: G. Y. H. Lip, J. L. Halperin, P. Petersen, G. M. Rodgers, D. Pall, R. W. Renfurm Tags: Original Article Source Type: research

Warfarin non-persistence among stroke patients with atrial fibrillation
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For AF patients with stroke a warfarin persistence rate of 0.45 after 2years has previously been reported. No consistent predictors for discontinuation have been established.
Source: Thrombosis Research - July 30, 2015 Category: Hematology Authors: Fredrik Björck, Henrik Renlund, Peter J. Svensson, Anders Själander Tags: Full length article Source Type: research

Warfarin persistence among stroke patients with atrial fibrillation
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For AF patients with stroke a warfarin persistence rate of 0.45 after 2years has previously been reported. No consistent predictors for discontinuation have been established.
Source: Thrombosis Research - July 30, 2015 Category: Hematology Authors: Fredrik Björck, Henrik Renlund, Peter J. Svensson, Anders Själander Tags: Full Length Article Source Type: research

Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

New reversal agent for factor Xa inhibitors shows promise
Commentary on: Siegal DM, Curnette JT, Connolly SJ, et al.. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24. Context Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K-antagonists (eg, warfarin) for the long-term management of stroke prevention for non-valvular atrial fibrillation or venous thromboembolic disease. Favourable side-effect profiles and absence of therapeutic monitoring are important benefits of these newer agents. Warfarin is readily reversed with fresh frozen plasma (FFP) or prothrombin complex concentrates.1 The first reversal ag...
Source: Evidence-Based Medicine - May 22, 2016 Category: Internal Medicine Authors: Ghadimi, K., Welsby, I. J. Tags: Clinical trials (epidemiology), Immunology (including allergy), Drugs: cardiovascular system, Stroke, Venous thromboembolism, Unwanted effects / adverse reactions Therapeutics/Prevention Source Type: research

Apixaban Use in LVAD Patient with Recurrent GI Bleeding and Recent Embolic Stroke
Background: Left ventricular assist devices (LVAD) have been shown to improve quality of life and decrease mortality in patients with advanced heart failure. GI bleeding and pump thrombosis are major complications associated with LVAD therapy. Warfarin is the mainstay of anticoagulation for these patients. However, warfarin therapy can be challenging due to a narrow therapeutic window, drug/food interactions and need for frequent monitoring. The direct oral anticoagulants (DOACs) have been shown to be non-inferior or superior to warfarin for preventing stroke and reducing the risk of bleeding in patients with AF.
Source: Journal of Cardiac Failure - July 23, 2016 Category: Cardiology Authors: Lisa Curran, Ali Cosgrove, Amy Clegg, Molly Reece, Bryan Bartle, Peter Van Trigt, Dalton McLean, Daniel Bensimhon Source Type: research

Massive pulmonary embolism with acute cor pulmonale
A 51-year-old immobilised man, while recovering at stroke rehabilitation, complained of sudden onset chest pain prior to an unconscious collapse. Observations on arrival were heart rate 120 bpm, blood pressure 80/60 mm Hg and oxygen saturations of 90% on 10 L of oxygen. ECG demonstrated new right bundle branch block (RBBB) with classical S1Q3T3 repolarisation abnormality of acute right heart strain (figure 1A). Urgent CT pulmonary angiogram revealed saddle pulmonary embolism with extensive thrombus burden (figure 1B). Transthoracic echocardiogram (TTE) showed acute right ventricular (RV) overload with c...
Source: Postgraduate Medical Journal - July 25, 2016 Category: Journals (General) Authors: Nelson, A. J., Wong, G. R., Roberts-Thomson, R., Parvar, S. L. Tags: Journalology, Drugs: cardiovascular system, Echocardiography, Pain (neurology), Stroke, Hypertension, Interventional cardiology, Ischaemic heart disease, Venous thromboembolism, Radiology, Pulmonary embolism, Clinical diagnostic tests, Vascular surgery, E Source Type: research

The clinical management of cerebral venous sinus thrombosis. a uk survey
Conclusion Overall respondents were confident in the use of heparin for the treatment of CVST. Respondents used LMWH predominantly, in keeping with EFNS guidance, yet in contrast to a previous European survey.1
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Lavin, T., Punter, M., Holland, M. Tags: Stroke ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research